Clinical Trials Directory

Trials / Recruiting

RecruitingNCT05722561

E-Cigarettes for Harm Reduction in Smokers With Opioid Use Disorder

Effectiveness and Impact of Counseling Enhanced With Electronic Cigarettes for Harm Reduction in Smokers With Opioid Use Disorder

Status
Recruiting
Phase
Phase 2
Study type
Interventional
Enrollment
302 (estimated)
Sponsor
NYU Langone Health · Academic / Other
Sex
All
Age
21 Years – 75 Years
Healthy volunteers
Not accepted

Summary

The purpose of this an open-label, randomized controlled trial study is to compare the effectiveness of electronic cigarettes (e-cigarettes/e-cigs) versus telehealth motivational counseling with combination nicotine replacement therapy (NRT) + telehealth counseling on combustible cigarettes smoking reduction among persons with opioid use disorder (OUD) in methadone and buprenorphine treatment programs (opioid use disorder treatment programs (OUDTP)). OUDTP patients are a population with exceptionally high combustible cigarettes smoking burden and yet limited success in achieving meaningful clinical outcomes in tobacco treatment. If effective, electronic cigarettes would provide an additional tool for tobacco harm reduction among this difficult-to-treat vulnerable population.

Conditions

Interventions

TypeNameDescription
BEHAVIORALTelehealth Motivational CounselingAt baseline, after randomization, participants will receive their first telehealth session (20\~25 minutes) from a counselor trained in motivational interviewing, harm reduction, and smoking cessation. Four additional sessions will be delivered (weeks 2, 3, 4, 6), 15\~20 minutes each.
DRUGNicotine Replacement ProductCombination nicotine replacement therapy with lozenges and patches. Participants are recommended to use the NRT according to product directions.
DEVICENational Institute on Drug Abuse (NIDA) Standardized Research Electronic Cigarette (SREC).Participants are to use the electronic cigarette freely as replacement for smoking combustible cigarettes.

Timeline

Start date
2024-08-08
Primary completion
2026-11-01
Completion
2027-03-01
First posted
2023-02-10
Last updated
2026-03-11

Locations

2 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT05722561. Inclusion in this directory is not an endorsement.